awmsg logo



ropinirole (Requip XL®)


Reference No. 266

Publication date:
15/09/2009


Appraisal information

ropinirole (Requip XL®) prolonged-release tablet


Company: GlaxoSmithKline
BNF category: Central nervous system
NMG meeting date: 15/07/2009
AWMSG meeting date: 12/08/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1409
Ministerial ratification: 11/09/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Ropinirole prolonged-release (Requip XL®) is recommended for use within NHS Wales for the treatment of idiopathic Parkinson’s disease in patients already taking ropinirole immediate-release tablets (Requip®) and in whom adequate symptomatic control has been established. Substitution of ropinirole prolonged-release tablets for ropinirole immediate-release may be used as: (i) Monotherapy, alone (without levodopa) in idiopathic Parkinson’s disease. (ii) Adjunctive therapy in addition to levodopa to control ‘on-off’ fluctuations which might permit a reduction in the total daily dose of levodopa. In order to limit errors, prolonged-release ropinirole should be prescribed by brand as Requip XL®. AWMSG is of the opinion that prolonged-release ropinirole (Requip XL®) may be suitable for shared care in accordance with appropriate guidance.
Final Appraisal Recommendation (FAR)
Download